
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is projected to achieve organic sales growth of 6.0-7.0% through 2025, with consensus estimates suggesting total revenue could reach approximately $44.69 billion, reflecting a 6.4% year-over-year increase. The company is experiencing robust growth across several key segments, including a notable 13.7% increase in its Electrophysiology business and double-digit growth in its Diabetes and Structural Heart portfolios. Furthermore, Abbott has a solid financial foundation, exemplified by its consistent dividend increases over the last 50 years and a strong balance sheet that positions it well for potential mergers and acquisitions.
Bears say
The financial outlook for Abbott Laboratories is negatively impacted by ongoing challenges related to Covid-19 testing, which saw a substantial decline in sales, falling from $265 million in Q3'24 to $69 million in Q3'25. Additionally, macroeconomic pressures, including inflation and foreign exchange fluctuations, combined with underwhelming performance in key markets such as China and slower-than-expected revenue from new medical products, further hinder growth prospects. Abbott's reliance on international sales, coupled with competitive pressures in the continuous glucose monitoring market, poses additional risks to the company's revenue stability and overall performance.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares